Tumour Topoisomerase II Alpha Protein Expression and Outcome After Adjuvant Dose-Dense Anthracycline-Based Chemotherapy

Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

Roman Rouzier, Charles M. Perou, W. Fraser Symmans et al. · Clinical Cancer Research · 2005 · 1.9K citations · Full text

Medicine, Cancer Biology, Oncology +17

Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer

Donald A. Berry, Constance Cirrincione, I. Craig Henderson et al. · JAMA · 2006 · 731 citations · Full text

Medicine, Endocrinology, Oncology +17

Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study.

DJ Slamon, W. Eiermann, Nicholas J. Robert et al. · Cancer Research · 2009 · 554 citations

Medicine, Oncology, Pharmacology +17

<i>HER2</i> and Responsiveness of Breast Cancer to Adjuvant Chemotherapy

Kathleen I. Pritchard, Lois E. Shepherd, Frances P. O’Malley et al. · New England Journal of Medicine · 2006 · 508 citations · Full text

Medicine, Oncology, Pharmacology +16

HER2 Status and Efficacy of Adjuvant Anthracyclines in Early Breast Cancer: A Pooled Analysis of Randomized Trials

Alessandra Gennari, Maria Pia Sormani, P. Pronzato et al. · JNCI Journal of the National Cancer Institute · 2007 · 370 citations

Medicine, Oncology, Pharmacology +13